The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $70.06

Today's change-1.55 -2.16%
Updated February 5 4:01 PM EST. Delayed by at least 15 minutes.
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $70.06

Today's change-1.55 -2.16%
Updated February 5 4:01 PM EST. Delayed by at least 15 minutes.

Charles River Laboratories International Inc down (U.S.)$1.55

Charles River Laboratories International Inc closed sharply lower Friday, dropping (U.S.)$1.55 or 2.16% to (U.S.)$70.06. Over the last five days, shares have lost 5.62% and are down 12.85% for the last year to date. This security has outperformed the S&P 500 by 8.49% during the last year.

Key company metrics

  • Open(U.S.) $71.61
  • Previous close(U.S.) $71.61
  • High(U.S.) $72.26
  • Low(U.S.) $69.27
  • Bid / Ask-- / --
  • YTD % change-12.85%
  • Volume1,149,875
  • Average volume (10-day)722,457
  • Average volume (1-month)703,129
  • Average volume (3-month)545,732
  • 52-week range(U.S.) $59.99 to (U.S.) $84.69
  • Beta1.34
  • Trailing P/E22.89×
  • P/E 1 year forward18.87×
  • Forward PEG2.00×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.06
Updated February 5 4:01 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.00%

Based on its net profit margin of 11.00%, Charles River Laboratories International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 26, 201509/26/2015Jun 27, 201506/27/2015Mar 28, 201503/28/2015Dec 27, 201412/27/2014
Revenue349340320330
Total other revenue--------
Total revenue349340320330
Gross profit138133120120
Total cost of revenue211207201210
Total operating expense294284277289
Selling / general / administrative76717170
Research & development--------
Depreciation / amortization6657
Interest expense (income), net operating--------
Unusual expense (income)--112
Other operating expenses, total--------
Operating income55564341
Interest income (expense), net non-operating-4-4-3-3
Gain (loss) on sale of assets--------
Other--------
Income before tax53603240
Income after tax38493229
Income tax, total1511012
Net income37493227
Total adjustments to net income--------
Net income before extra. items37493228
Minority interest0-10-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items37493228
Inc. avail. to common incl. extra. items37493227
Diluted net income37493227
Dilution adjustment----00
Diluted weighted average shares47484848
Diluted EPS excluding extraordinary itemsvalue per share0.791.020.660.59
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.791.030.681.25